- UCL Neuroscience rated top by research strength in the REF2014
- $5.9 million boost for SUDEP research
- Secret of tetanus toxicity offers new way to treat motor neuron disease
- Harm to others outweighs harm to self in moral decision making
- Auto anomaly detection for brain imaging awarded £1m grant
- Spinal surgery: OECs studies to start in 2015
- New brain tumour research Centre of Excellence is unveiled
- UCL awarded £13.5 million to advance medical research facilities
- UCL research helps paralysed man to recover function
- Stenting safe and effective for long-term stroke prevention
- Department of Clinical & Experimental Epilepsy re-designated as a WHO Collaborating Centre
- Leonard Wolfson Experimental Neurology Centre open evening
- Brain stimulation to improve cognition in dementia
- Professor Lees receives Jay Van Andel Award for Outstanding Research in Parkinson’s Disease
- Creating brain cells from skin to study Alzheimer's
- Queen Square authors prominent in Brain collection of classic articles
- Toxic proteins implicated in frontotemporal dementia and motor neurone disease
- GCH1 gene and Parkinson’s risk
- Double mutation linked to frontotemporal dementia
- Equation to predict happiness
- Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia
- Researchers test whether diabetes drug can help Parkinson’s patients
- Acute optic neuritis: a review and proposed protocol
- Hippocampal subfield size predicts the precision of memory recall
- Immune system implicated in dementia development
- UCL and Chiesi Group announce partnership to develop a novel therapeutic for birth asphyxia
- Professor Golay made a Fellow of the ISMRM
- The new Leonard Wolfson Experimental Neurology Centre (LWENC) has opened for clinical studies and trials
- Professor Rees wins UCLU Student Choice Teaching Award
- New epilepsy treatment offers ‘on demand’ seizure suppression
- Professor Tabrizi and Professor Price elected to Fellowship of the Academy of Medical Sciences.
- Professor Dolan and Professor Friston elected to EMBO membership
- Vitamin B3 treatment for ataxia shows promise in first human trial
- Teaching Awards 2014
- Light-activated neurons from stem cells restore function to paralysed muscles
- UCL and Max Planck Society invest €5m to open world’s first computational psychiatry centre
- Successful launch of new annual leading edge neurology course
- Statins could help control MS
- Professor Hardy awarded Thudichum Medal by Biochemical Society
- Population Screening for vCJD Using a Novel Blood Test
- Chief Medical Officer appoints Professor Rossor as NIHR National Director for Dementia Research
- New partnership between UCLP brain tumour scientists and Brain Tumour Research
- Professor Hardy awarded Dan David Prize for work on the amyloid gene encoding APP
- NIHR award £650,000 for research into rare neurodegenerative and neuromuscular diseases
- Lowering levels of toxic protein reverses abnormalities in cells from patients with Huntington's disease
Published: Oct 10, 2014 5:54:41 PM
Published: Oct 22, 2014 9:52:00 AM
Published: Sep 16, 2013 1:37:21 PM
Published: Feb 24, 2014 2:53:53 PM
Published: Dec 19, 2014 2:44:33 PM
Published: Jul 30, 2014 1:47:13 PM
UCL and Chiesi Group announce partnership to develop a novel therapeutic for birth asphyxia
18 June 2014
The Chiesi Group and UCL (University College London) are collaborating to test a novel melatonin formulation as a brain protective medicine for babies who suffer birth asphyxia.
The collaboration is supported by UCL Business PLC (UCLB), UCL’s wholly owned technology transfer company, who have granted Chiesi access to specific research knowledge developed by Professor Nicola Robertson, a renowned expert in the field of neonatal neuroscience and neuroprotection and Professor Xavier Golay (Head of Brain Repair and Rehabilitation at UCL Institute of Neurology), an expert in the field of physiological MRI and image-based biomarkers.
Chiesi will be responsible for the development of a melatonin formulation suitable for neonatal use and for the subsequent full development of the product including the clinical trial program, while UCL, as part of this collaboration, will be entitled to receive royalties on future sales in addition to other undisclosed payments.
Birth asphyxia is a very serious clinical condition caused by temporary but abrupt interruption of the constant blood flow to the brain around the time of birth. In Europe, US and Australia the incidence of birth asphyxia is 2-3 cases per 1000 births at term; in mid and low resource settings the incidence can be 5-20 times more common. Globally, birth asphyxia is the fifth leading cause of child deaths and there is a significant burden of disability as children mature. In 2010, birth asphyxia was the cause of 2.4% of the Global Burden of Disease and 6.1 million years of life with disability.
We are very excited about the collaboration. Even though therapeutic hypothermia is used in many hospitals, cooling is only partially effective and other medicines are desperately needed to optimally treat birth asphyxia.
Despite excellent maternity services and the significant improvement in birth asphyxia outcomes following the introduction of therapeutic hypothermia, around 40% of infants still have an abnormal neurodevelopmental outcome. Melatonin is a natural hormone mainly secreted at night, which in pharmacological doses can add to hypothermia to protect the baby brain from damage.
Professor Nicola Robertson (Institute of Child Health)
Consequences of birth asphyxia include devastating disabilities such as cerebral palsy, cognitive, hearing, language and speech impairments, epilepsy and delay in development. These have serious effects on the individual, the family, society and the economy. The clinical need for novel, safe and effective therapies to optimise brain protection following birth asphyxia is therefore paramount.
This is an excellent partnership for both parties, combining the world class translational research strengths of Professors Robertson and Golay, along with their colleagues at UCL with the significant development and commercialisation capabilities of the Chiesi Group, to progress this important therapy to market
Dr Chris Williams, Senior Business Manager at UCLB
Our company has a strong track record in the field of neonatology and we are very proud and pleased to contribute to the healthcare of this vulnerable and important patient population. We are currently leveraging our established product developments and emerging pipeline to expand our work into additional areas of high unmet medical need for neonates. In this regard, we look forward to executing on the promise of this exciting partnership with UCL which we recognise as a centre of excellence in the field.
Dr Paolo Chisi, Vice President and Director of Research & Development for the Chiesi Group
Page last modified on 18 jun 14 17:07